iRadimed (NASDAQ:IRMD) Updates FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.060-2.210 for the period, compared to the consensus earnings per share estimate of 2.040. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.0 million. iRadimed also updated its Q1 2026 guidance to 0.440-0.480 EPS.

iRadimed Stock Down 3.5%

NASDAQ IRMD traded down $3.62 on Thursday, reaching $99.47. The company had a trading volume of 19,286 shares, compared to its average volume of 76,601. The stock has a market capitalization of $1.27 billion, a PE ratio of 56.84 and a beta of 1.11. iRadimed has a 12 month low of $47.48 and a 12 month high of $107.90. The firm’s 50 day moving average price is $98.28 and its 200 day moving average price is $83.57.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.85% and a net margin of 26.82%.The firm had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, research analysts expect that iRadimed will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Monday, February 23rd will be issued a dividend of $0.20 per share. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed’s payout ratio is currently 38.86%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Mkm reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Tuesday. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, iRadimed presently has an average rating of “Moderate Buy” and an average target price of $120.00.

Insider Buying and Selling at iRadimed

In other news, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the transaction, the chief executive officer owned 2,262,500 shares in the company, valued at approximately $227,720,625. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 55,000 shares of company stock worth $5,287,900 in the last ninety days. 36.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iRadimed

Hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank raised its stake in shares of iRadimed by 3.2% during the fourth quarter. Swiss National Bank now owns 16,300 shares of the medical equipment provider’s stock valued at $1,586,000 after acquiring an additional 500 shares in the last quarter. Aviva PLC purchased a new position in iRadimed during the 4th quarter worth $519,000. Deutsche Bank AG increased its holdings in iRadimed by 10.9% during the 4th quarter. Deutsche Bank AG now owns 5,879 shares of the medical equipment provider’s stock worth $572,000 after purchasing an additional 577 shares during the period. Cerity Partners LLC bought a new stake in iRadimed during the 4th quarter valued at $261,000. Finally, Franklin Resources Inc. lifted its holdings in shares of iRadimed by 39.5% in the 4th quarter. Franklin Resources Inc. now owns 15,828 shares of the medical equipment provider’s stock worth $1,540,000 after buying an additional 4,480 shares during the period. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.